Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations research discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://stephenp975ors7.creacionblog.com/profile